Orthopedic practice is moving away from a model that manages knee pain until the joint fails, toward early structural intervention, a shift that raises the bar for what a cartilage repair product must deliver. Regentis Biomaterials Ltd. (NYSE American: RGNT) is developing GelrinC, a cell-free hydrogel implant for focal knee cartilage defects, in a market that is redefining treatment goals. The company’s approach aligns with a broader change in how degenerative knee disease is addressed.
For much of the last three decades, treatment of degenerative knee disease has centered heavily on managing symptoms with anti-inflammatories, activity modification, lubricants and injections, while structural intervention was often reserved for more advanced disease. Focal cartilage defects had surgical options, but those came with tradeoffs in durability, complexity, and cost. That balance is shifting. Regentis’ GelrinC is an acellular hydrogel implant designed to erode in a controlled, synchronized manner as surrounding cells regenerate hyaline-like cartilage. Phase II data showed approximately 100% greater KOOS improvement than microfracture at two years.
The product has CE Mark approval in Europe, and pivotal U.S. trial enrollment is targeted for completion by approximately year end 2026. Platform work is also extending toward moderate osteoarthritis. These milestones position Regentis to address a market that is increasingly focused on early structural repair rather than symptom management alone. The latest news and updates relating to RGNT are available in the company’s newsroom at https://nnw.fm/RGNT.
This content was disseminated on behalf of Regentis Biomaterials Ltd. (NASDAQ: RGNT) as part of a paid marketing engagement with IBN.Ai. IBN will receive $30,000 per quarter for a total of 180 days from RGNT for coverage via IBN. Full terms of use and disclaimers are available on the IBN website at https://www.BioMedWire.com/Disclaimer.
The dissemination was managed by NetworkNewsWire, a specialized communications platform focused on financial news and content distribution. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN. The platform provides access to wire solutions via InvestorWire, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution, and tailored corporate communications solutions. For more information, visit https://www.NetworkNewsWire.com. Full terms of use and disclaimers are on the NetworkNewsWire website at https://www.NetworkNewsWire.com/Disclaimer.
